Institute of Hematology & Blood Diseases Hospital, China: Lymphoma, B-Cell trials

The registry lists 12 Lymphoma, B-Cell studies with Institute of Hematology & Blood Diseases Hospital, China as lead sponsor. 6 are open to participants now and 0 have results posted.

Early Phase 1 1Phase 1 7Phase 2 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell LymphomaNot yet recruitingNCT07539688Phase 1
• A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell NeoplasmsNot yet recruitingNCT07234045Phase 1
• A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT07068906Phase 1
• Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaRecruitingNCT06996132Phase 2
• Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLRecruitingNCT06489808Phase 2
• Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaRecruitingNCT06415708Phase 2
• A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06464185Phase 1/2
• Targeting CD19/CD20/CD22 Triple-targeted Cell in Patients With Relapsed/Refractory B-cell LymphomaTerminatedNCT05318963Phase 1
• CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell LymphomaCompletedNCT04690192Phase 1/2
• γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)Status unknownNCT04028440Early Phase 1
• DLCL002 Protocol for Patients With High Risk Aggressive B-cell LymphomaStatus unknownNCT03837873Phase 2
• CD19 CAR T Cells in Patients With Relapsed or Refractory CD19 Positive B-cell LymphomaCompletedNCT03029338Phase 1